UBS Asset Management Americas Inc. Cuts Position in AMAG Pharmaceuticals, Inc. (AMAG)

UBS Asset Management Americas Inc. decreased its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 50.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,199 shares of the specialty pharmaceutical company’s stock after selling 8,457 shares during the period. UBS Asset Management Americas Inc.’s holdings in AMAG Pharmaceuticals were worth $285,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans increased its stake in AMAG Pharmaceuticals by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,380 shares of the specialty pharmaceutical company’s stock worth $640,000 after buying an additional 1,000 shares during the last quarter. Rhumbline Advisers increased its stake in AMAG Pharmaceuticals by 2.2% in the third quarter. Rhumbline Advisers now owns 53,339 shares of the specialty pharmaceutical company’s stock worth $1,307,000 after buying an additional 1,130 shares during the last quarter. New York State Teachers Retirement System increased its stake in AMAG Pharmaceuticals by 5.0% in the fourth quarter. New York State Teachers Retirement System now owns 25,325 shares of the specialty pharmaceutical company’s stock worth $881,000 after buying an additional 1,200 shares during the last quarter. BlackRock Investment Management LLC increased its stake in AMAG Pharmaceuticals by 1.1% in the third quarter. BlackRock Investment Management LLC now owns 155,151 shares of the specialty pharmaceutical company’s stock worth $3,803,000 after buying an additional 1,661 shares during the last quarter. Finally, Comerica Bank increased its stake in AMAG Pharmaceuticals by 5.1% in the fourth quarter. Comerica Bank now owns 36,399 shares of the specialty pharmaceutical company’s stock worth $837,000 after buying an additional 1,764 shares during the last quarter.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 19.25 on Thursday. AMAG Pharmaceuticals, Inc. has a one year low of $17.90 and a one year high of $36.83. The company’s 50-day moving average price is $21.35 and its 200-day moving average price is $25.81. The stock’s market cap is $674.62 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. The firm had revenue of $139.47 million during the quarter, compared to analysts’ expectations of $150.32 million. During the same period last year, the company earned ($0.22) earnings per share. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. Analysts forecast that AMAG Pharmaceuticals, Inc. will post $5.13 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “UBS Asset Management Americas Inc. Cuts Position in AMAG Pharmaceuticals, Inc. (AMAG)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://sportsperspectives.com/2017/05/25/ubs-asset-management-americas-inc-cuts-position-in-amag-pharmaceuticals-inc-amag.html.

A number of research firms have weighed in on AMAG. Jefferies Group LLC set a $40.00 price target on AMAG Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, March 18th. ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. Barclays PLC restated a “hold” rating and set a $25.00 price target on shares of AMAG Pharmaceuticals in a research report on Monday, May 15th. Cantor Fitzgerald set a $24.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, February 14th. Finally, TheStreet downgraded AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $30.00.

In related news, SVP Julie Krop sold 1,891 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the sale, the senior vice president now directly owns 36,777 shares of the company’s stock, valued at approximately $899,197.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.30% of the company’s stock.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

12 Month Chart for NASDAQ:AMAG

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply